Twin Acquisitions, China-wide Plasma Shortage, Boost Earnings For China Biologic
This article was originally published in PharmAsia News
Executive Summary
BEIJING - The leadership of China Biologic Products, the country's biggest privately held provider of plasma-based biopharmaceuticals, said that the acquisition of two competitors earlier this year helped elevate profits in the second quarter, and that the emergence of the A/H1N1 pandemic could bolster sales throughout the year
You may also be interested in...
Acquisitions Catapult China Biologic Into Leading Biopharma Outfit; Position It For Global Competition With U.S., EU Players
BEIJING - The chief executive officer of China Biologic Products Inc. said an aggressive acquisition strategy has helped transform the company into China's leading privately held provider of plasma-based biopharmaceuticals, and that the outfit is aiming to expand its geographical footprint across the globe
China’s SFDA To Require Electronic Tags For All Domestic Drugs; Imported Pharmaceuticals Likely To Follow
BEIJING - China's State FDA has issued a series of regulations in recent months that will ultimately require all pharmaceuticals, biologics and medical devices produced domestically to carry electronic tags with essential identifying information
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).